Senti Biosciences (SNTI) Competitors $2.27 +0.02 (+0.89%) (As of 12:25 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SNTI vs. ACHL, NXTC, CARM, ANEB, LTRN, VRCA, DRRX, PASG, LUMO, and OKYOShould you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include Achilles Therapeutics (ACHL), NextCure (NXTC), Carisma Therapeutics (CARM), Anebulo Pharmaceuticals (ANEB), Lantern Pharma (LTRN), Verrica Pharmaceuticals (VRCA), DURECT (DRRX), Passage Bio (PASG), Lumos Pharma (LUMO), and OKYO Pharma (OKYO). These companies are all part of the "pharmaceutical products" industry. Senti Biosciences vs. Achilles Therapeutics NextCure Carisma Therapeutics Anebulo Pharmaceuticals Lantern Pharma Verrica Pharmaceuticals DURECT Passage Bio Lumos Pharma OKYO Pharma Achilles Therapeutics (NASDAQ:ACHL) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, community ranking, institutional ownership, risk and dividends. Do insiders & institutionals have more ownership in ACHL or SNTI? 56.4% of Achilles Therapeutics shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 5.4% of Achilles Therapeutics shares are held by insiders. Comparatively, 15.9% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community prefer ACHL or SNTI? Achilles Therapeutics received 14 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 54.84% of users gave Achilles Therapeutics an outperform vote while only 33.33% of users gave Senti Biosciences an outperform vote. CompanyUnderperformOutperformAchilles TherapeuticsOutperform Votes1754.84% Underperform Votes1445.16% Senti BiosciencesOutperform Votes333.33% Underperform Votes666.67% Is ACHL or SNTI more profitable? Achilles Therapeutics' return on equity of -47.24% beat Senti Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Achilles TherapeuticsN/A -47.24% -41.69% Senti Biosciences N/A -84.70%-48.10% Which has more risk and volatility, ACHL or SNTI? Achilles Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.74, suggesting that its share price is 174% more volatile than the S&P 500. Does the media prefer ACHL or SNTI? In the previous week, Achilles Therapeutics had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Achilles Therapeutics and 1 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 1.87 beat Achilles Therapeutics' score of 1.44 indicating that Senti Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Achilles Therapeutics Positive Senti Biosciences Very Positive Do analysts recommend ACHL or SNTI? Achilles Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 292.16%. Given Achilles Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Achilles Therapeutics is more favorable than Senti Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achilles Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings & valuation, ACHL or SNTI? Achilles Therapeutics has higher earnings, but lower revenue than Senti Biosciences. Achilles Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchilles TherapeuticsN/AN/A-$69.67M-$1.59-0.64Senti Biosciences$2.56M4.03-$71.06M-$12.65-0.18 SummaryAchilles Therapeutics beats Senti Biosciences on 11 of the 16 factors compared between the two stocks. Ad Golden CrestIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopping, and the digital dollar is coming. You can protect yourself—but only if you act now. Don't wake up too late. Get your Digital Dollar Protection today and secure your retirement before the window closes.Click Here For Your Free Guide Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNTI vs. The Competition Export to ExcelMetricSenti BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.31M$3.13B$5.22B$8.94BDividend YieldN/A1.76%4.98%4.03%P/E Ratio-0.1836.18124.8816.69Price / Sales4.03312.921,276.9391.02Price / CashN/A179.8138.8936.42Price / Book0.154.446.395.98Net Income-$71.06M-$42.42M$118.47M$225.08M7 Day Performance2.27%-2.34%-1.94%-0.37%1 Month Performance6.13%5.65%2.65%4.23%1 Year Performance-35.71%37.92%36.44%27.64% Senti Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNTISenti Biosciences0.9331 of 5 stars$2.27+0.9%N/A-48.2%$10.40M$2.56M-0.184Positive NewsGap DownACHLAchilles Therapeutics2.9046 of 5 stars$1.01flatN/A+26.1%$41.50MN/A-0.64250Short Interest ↓News CoveragePositive NewsGap UpNXTCNextCure4.5634 of 5 stars$1.46-5.2%N/A+25.9%$40.90MN/A-0.7090Analyst ForecastGap UpCARMCarisma Therapeutics3.3038 of 5 stars$0.97-2.5%N/A-60.0%$40.50M$14.92M-0.6220Earnings ReportShort Interest ↓ANEBAnebulo Pharmaceuticals3.2151 of 5 stars$1.55-6.1%N/A-28.9%$40.19MN/A-4.844Short Interest ↓News CoveragePositive NewsGap UpLTRNLantern Pharma0.8901 of 5 stars$3.57-0.3%N/A-6.4%$38.49MN/A-2.0120Analyst RevisionVRCAVerrica Pharmaceuticals4.7183 of 5 stars$0.83-9.3%N/A-71.9%$38.04M$5.12M-0.4640Analyst RevisionDRRXDURECT3.3148 of 5 stars$1.22-5.4%N/A+130.1%$37.87M$8.55M-2.0080Analyst ForecastNews CoverageGap UpPASGPassage Bio3.6388 of 5 stars$0.61-9.2%N/A-3.0%$37.46MN/A-0.45130Analyst ForecastPositive NewsGap UpLUMOLumos Pharma3.0146 of 5 stars$4.30-1.4%N/A+38.7%$37.20M$2.05M-1.0030Short Interest ↓OKYOOKYO Pharma2.6616 of 5 stars$1.08flatN/A-34.9%$36.55MN/A0.007Short Interest ↑ Related Companies and Tools Related Companies Achilles Therapeutics Alternatives NextCure Alternatives Carisma Therapeutics Alternatives Anebulo Pharmaceuticals Alternatives Lantern Pharma Alternatives Verrica Pharmaceuticals Alternatives DURECT Alternatives Passage Bio Alternatives Lumos Pharma Alternatives OKYO Pharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNTI) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopp...Golden Crest | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNTI Stock Alerts